Alnylam's updated lumasiran data points to PhIII short track; Genentech snatches fourth approval for Rituxan
→ Alnylam $ALNY came out with some updated data from a Phase I/II study Friday, showing the company’s rare disease drug lumasiran is on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
